Cargando…
Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG
PURPOSE: This study aimed to investigate the ability of Al(18)F-NOTA-FAPI PET/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of (18)F-FDG PET/CT. METHODS: Prospective analysis of Al(18)F-NOTA-FAPI PET/CT and (18)F-FDG PET/CT scans of 31 patients from 05/202...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496317/ https://www.ncbi.nlm.nih.gov/pubmed/37700343 http://dx.doi.org/10.1186/s40644-023-00596-1 |
_version_ | 1785105080171626496 |
---|---|
author | Lyu, Zhehao Han, Wei Zhang, Qi Zhao, Hongyue Liu, Shan Wang, Yan He, Jin Zhao, Changjiu Tian, Lin Fu, Peng |
author_facet | Lyu, Zhehao Han, Wei Zhang, Qi Zhao, Hongyue Liu, Shan Wang, Yan He, Jin Zhao, Changjiu Tian, Lin Fu, Peng |
author_sort | Lyu, Zhehao |
collection | PubMed |
description | PURPOSE: This study aimed to investigate the ability of Al(18)F-NOTA-FAPI PET/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of (18)F-FDG PET/CT. METHODS: Prospective analysis of Al(18)F-NOTA-FAPI PET/CT and (18)F-FDG PET/CT scans of 31 patients from 05/2021 to 05/2022 were analyzed. Al(18)F-NOTA-FAPI imaging was performed in patients who had Ce-CT and FDG PET/CT and the diagnosis was still unclear. Follow-up histopathology or radiographic examination confirmed the findings. Radiotracer uptake, diagnostic performance, and TNM (tumor-node-metastasis) classifications were compared. RESULTS: A total of 31 patients with pancreatic carcinoma (all were adenocarcinoma) underwent Al(18)F-NOTA-FAPI-04 PET/CT, including 20 male and 11 female patients, with a mean age of 58.2 ± 8.5 years. FAPI-04 PET/CT imaging showed a higher value of SUV(max-15min/30min/60min), SUV(mean-15min/30min/60min), TBR(1), and TBR(2) in pancreatic carcinoma than FDG (all P < 0.01). The mean level of Al(18)F-NOTA FAPI-04 uptake values of the pancreatic ductal adenocarcinoma was higher than that of pancreatitis in both SUV(max-30min) (P < 0.01)(,) SUV(mean-30min) (P < 0.05), SUV(max-60min) (P < 0.01)(,) and SUV(mean-60min) (P < 0.01). The FAPI △SUV(max-1), △SUV(max-2), and △SUV(mean-2) uptake values of pancreatic carcinoma were higher than tumor-associated inflammation (all P < 0.01). TNM staging of 16/31 patients changed after Al(18)F-NOTA FAPI-04 PET/CT examination with all upstaging changes. CONCLUSION: Al(18)F-NOTA-FAPI-04 PET/CT at 15 and 30 min also demonstrated an equivalent detection ability of pancreatic lesion to (18)F-FDG PET/CT. Delayed-phase Al(18)F-NOTA-FAPI-04 PET/CT can help differentiate pancreatic carcinoma and tumor-associated inflammation. Al(18)F-NOTA FAPI-04 PET/CT also performed better than FDG PET/CT in TNM staging. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100051406. Registered 23 September 2021, https://www.chictr.org.cn/showproj.html?proj=133033 |
format | Online Article Text |
id | pubmed-10496317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104963172023-09-13 Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG Lyu, Zhehao Han, Wei Zhang, Qi Zhao, Hongyue Liu, Shan Wang, Yan He, Jin Zhao, Changjiu Tian, Lin Fu, Peng Cancer Imaging Research Article PURPOSE: This study aimed to investigate the ability of Al(18)F-NOTA-FAPI PET/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of (18)F-FDG PET/CT. METHODS: Prospective analysis of Al(18)F-NOTA-FAPI PET/CT and (18)F-FDG PET/CT scans of 31 patients from 05/2021 to 05/2022 were analyzed. Al(18)F-NOTA-FAPI imaging was performed in patients who had Ce-CT and FDG PET/CT and the diagnosis was still unclear. Follow-up histopathology or radiographic examination confirmed the findings. Radiotracer uptake, diagnostic performance, and TNM (tumor-node-metastasis) classifications were compared. RESULTS: A total of 31 patients with pancreatic carcinoma (all were adenocarcinoma) underwent Al(18)F-NOTA-FAPI-04 PET/CT, including 20 male and 11 female patients, with a mean age of 58.2 ± 8.5 years. FAPI-04 PET/CT imaging showed a higher value of SUV(max-15min/30min/60min), SUV(mean-15min/30min/60min), TBR(1), and TBR(2) in pancreatic carcinoma than FDG (all P < 0.01). The mean level of Al(18)F-NOTA FAPI-04 uptake values of the pancreatic ductal adenocarcinoma was higher than that of pancreatitis in both SUV(max-30min) (P < 0.01)(,) SUV(mean-30min) (P < 0.05), SUV(max-60min) (P < 0.01)(,) and SUV(mean-60min) (P < 0.01). The FAPI △SUV(max-1), △SUV(max-2), and △SUV(mean-2) uptake values of pancreatic carcinoma were higher than tumor-associated inflammation (all P < 0.01). TNM staging of 16/31 patients changed after Al(18)F-NOTA FAPI-04 PET/CT examination with all upstaging changes. CONCLUSION: Al(18)F-NOTA-FAPI-04 PET/CT at 15 and 30 min also demonstrated an equivalent detection ability of pancreatic lesion to (18)F-FDG PET/CT. Delayed-phase Al(18)F-NOTA-FAPI-04 PET/CT can help differentiate pancreatic carcinoma and tumor-associated inflammation. Al(18)F-NOTA FAPI-04 PET/CT also performed better than FDG PET/CT in TNM staging. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2100051406. Registered 23 September 2021, https://www.chictr.org.cn/showproj.html?proj=133033 BioMed Central 2023-09-12 /pmc/articles/PMC10496317/ /pubmed/37700343 http://dx.doi.org/10.1186/s40644-023-00596-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Lyu, Zhehao Han, Wei Zhang, Qi Zhao, Hongyue Liu, Shan Wang, Yan He, Jin Zhao, Changjiu Tian, Lin Fu, Peng Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG |
title | Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG |
title_full | Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG |
title_fullStr | Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG |
title_full_unstemmed | Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG |
title_short | Clinical application of Al(18)F-NOTA-FAPI PET/CT in diagnosis and TNM staging of pancreatic adenocarcinoma, compared to (18)F-FDG |
title_sort | clinical application of al(18)f-nota-fapi pet/ct in diagnosis and tnm staging of pancreatic adenocarcinoma, compared to (18)f-fdg |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496317/ https://www.ncbi.nlm.nih.gov/pubmed/37700343 http://dx.doi.org/10.1186/s40644-023-00596-1 |
work_keys_str_mv | AT lyuzhehao clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT hanwei clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT zhangqi clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT zhaohongyue clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT liushan clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT wangyan clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT hejin clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT zhaochangjiu clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT tianlin clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg AT fupeng clinicalapplicationofal18fnotafapipetctindiagnosisandtnmstagingofpancreaticadenocarcinomacomparedto18ffdg |